Furthermore, SLAMF3 and SLAMF6 receptors on T cell surfaces have been reported to be positively associated with disease activity in SLE patients, possibly via increasing IL-17 production [57]. This evidence concerns the gene SLAMF6 and systemic lupus erythematosus.